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Abstract
Approximately 3-15% of all malignant melanomas (MM) are familial cases. MM is a highly heterogeneous tumour
type from a genetic perspective. Pedigrees with disease confined to a single generation of siblings or MM occurring
among second- or third-degree relatives suggest multifactorial polygenic inheritance. However, not infrequently,
within large families aggregations of MM are consistent with autosomal dominant inheritance, suggesting a hereditary
syndrome caused by germline alterations of a single gene. Several different genes are involved in the development
of MM. However, even when taken together they are responsible for less than 20% of all MM cases. It is thus necessary
to perform association studies focused on genetic markers that could be used in identifying patients with a high risk
of MM. Evaluation of aggregations of MM and other malignancies, like breast cancer, could be essential in identifying
relatives of MM probands being at high risk of developing malignancies other than MM. The ultimate goal is to
apply in these cases prevention recommendations and surveillance protocols to reduce the disease risk.
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Epidemiology 
Malignant melanoma (MM) is one of the most
aggressive human malignancies. The incidence rates
differ among Caucasian populations: ~35 per 100 000
in Australia [1], ~10 per 100 000 in the United States
[2], ~7-10 per 100 000 in Western Europe [3, 4]. Its
incidence has increased dramatically over the past years
in Caucasian population worldwide up to a 10-fold
increase since 1950s [5]. 
Risk factors
Sun exposure
Well-established environmental risk factor of MM is
ultraviolet radiation (UV), sunburn and overexposure to
the sun [6]. Armstrong and Kricker estimated that up to
65% of MM could be related to sunburn [7]. Exposure
in childhood seems to be an especially important risk
factor [8]. In countries with a growing awareness of MM
and public health campaigns to avoid UV a downturn
in MM incidence has been observed [9]. 
Genetic factors
It has been long stated in many different reviews that
genetic susceptibility is another major MM risk factor.
Recent epidemiological studies confirm these
suggestions. Evaluation of over eight thousand Swedish
probands with primary MM revealed that the familial
risk for offspring of affected parents is about 2.57, and
even higher (4.22) when a parent has been diagnosed
at an age <50 years [10]. Similar results were obtained
during the evaluation of 1505 MM probands recorded
in Utah (USA) when the familial risk for first-degree
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relatives (both offspring and siblings) was 2.1, and as
high as 6.52 when MM cases were diagnosed under 50
years [11]. Hemminki et al reported that the familial MM
risk showed a clear age dependence and higher risk in
in situ melanoma than in its invasive counterpart [12]. 
Familial clustering of MM has also been studied in
twins. A population-based study of cancer risk in twins
performed by Swerdlow et al indicated an increased
risk of the occurrence of MM in opposite-sex co-twins,
however studies performed by Hemminki and Milan
did not confirm these results [13, 14, 15]. 
Familial aggregations of malignancy may be due to
either genetic factors, environmental factors shared by
family members, or both. In a recent study Czene et al
assessed the genetic and environmental components in
the main types of cancer by statistical analyses of family
pairs. The importance of genetic effects was indicated by
a higher correlation among relatives that were more
closely related to each other genetically. Structural
equation modelling was used to derive estimates of the
importance of environmental and genetic effects.
A statistically significant proportion of susceptibility to
cancer accounted for by genetic effects was obtained for
almost all malignancies, including MM. It was estimated
that in the case of MM genetic factors constitute 21% of
susceptibility, similarly to other neoplasms, such as cancers
of breast, colon or stomach [16]. 
Familial aggregations of MM
There are two distinct ways of defining familial
melanoma: 1) occurrence of melanoma in at least two
first-degree relatives; or 2) families with at least two
melanomas irrespective of the degree of relationship. 
Approximately 3-15% of all MM are familial cases
of any type [17]. In Australia, Holman and Armstrong
found a positive family history in 15% of 507 cases
(9.9% in first-degree relatives) [18]. In the USA MM was
present in first-degree relatives in 4.1% of 116 cases
[19], in Denmark among 474 patients 4.7% had
a relative with MM (3% in first-degree relatives) [20]. In
our center among 405 unselected MM patients 12
cases (3%) had at least one first-degree relative affected. 
In several families the co-occurrence of melanoma
of the skin and the eye is reported [21]. The question
whether ocular melanoma is also part of the familial
melanoma syndrome remains unanswered. 
Familial MM constitutes most probably
a heterogeneous group of disorders characterized by
occurrence of MM among relatives. The mode of
inheritance is controversial and according to Mao is
most likely polygenic [22]. Pedigrees with disease
confined to a single generation of siblings or MM
occurring among second- or third-degree relatives
suggest multifactorial polygenic inheritance. However,
not infrequently, within large families aggregations of
MM are consistent with autosomal dominant
inheritance. Anderson et al described MM in at least
15 members of a three-generation kindred. Early age
of onset and a tendency for multiple primary lesions
were characteristic features [23]. Lynch and Krush
(1968) described two families with malignant
melanoma in two generations in one family and three
generations in the other [24]. Such pedigrees strongly
suggest that part of familial MM constitutes hereditary
syndrome caused by single-gene germline alterations.
In order to identify such families the first definition of
familial melanoma described above should be used. 
Familial aggregations of MM 
and malignancies at different sites of origin
Aggregations of MM and other malignancies have
been reported by many authors. 
Most significantly a high incidence of pancreatic
cancer has been reported in melanoma families, either
by itself or in association with breast cancer [25-27]. 
Weston et al described a case with familial
aggregation of melanoma, basal cell carcinoma and
gastric cancer [28]. Aggregations of MM and cerebral
astrocytoma [29], squamous cell carcinoma (SCC) [30]
and kidney [31] were described. Recently, an increased
risk of breast cancer among first-degree relatives of
MM probands from families with strong cancer familial
aggregation (showing features of autosomal dominant
pattern of inheritance) has been suggested [32]. 
Fig. 1. Pedigree of a family with melanoma diagnosed among
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Molecular background 
of familial melanoma
Genes conferring high risk of developing MM
CDKN2A
In 1994 the first and so far the most significant
high-risk MM susceptibility gene, CDKN2A (9p21,
OMIM 600160) was identified [33, 34]. One of the
four transcripts coded by this gene is the p16 protein.
It inhibits the activity of the complex of cyclin D1 with
cyclin-dependent kinase 4 (CDK4) or 6 (CDK6), the
function of which is to promote cellular proliferation
[35]. Thus CDKN2A acts as a tumour suppressor gene
by inhibiting cellular proliferation. 
Germline mutation frequencies in CDKN2A among
members of melanoma families show considerable
variation. Soufir et al showed frequent involvement of
CDKN2A in French familial melanoma families (46%)
whereas Fitzgerald et al identified 18% of US familial
melanoma harboured CDKN2A constitutional mutations
[36, 37]. Among Swedish families only 8% of cases
were found to harbour alterations in the CDKN2A gene
[38, 39]. Germline mutation and large deletion analysis
of the CDKN2A/ARF genes in Polish families with
multiple melanomas and in families with an aggregation
of MM and breast cancer revealed that less than 6% of
familial MM can be associated with the CDKN2A/ARF
constitutional mutations [40]. In a separate study done
by Lamperska et al no CDKN2A mutations have been
detected in Polish melanoma-prone families [41]. 
According to Bressac-de-Paillerets et al the number
of CDKN2A alterations correlates with the number of
MM cases in the family and a young age at diagnosis
(<50) [42]. However, no germline mutations have been
reported in childhood melanoma so far [43]. 
In Dutch melanoma-prone families with a specific
recurrent 19bp deletion of exon 2 of the CDKN2A
gene, a high frequency of pancreatic cancer was
observed [44]. CDKN2A was the first of the melanoma
genes and is associated with an increase in the risk of
pancreatic cancer as well [45]. Occurrence of multiple
MM, pancreatic cancer and also breast cancer has
been reported in families with different recurrent
CDKN2A constitutional alterations [46]. 
In a recent study Bishop et al examined 80 families
with documented CDKN2A mutations and multiple cases
of cutaneous melanoma to establish the penetrance of
the CDKN2A germline mutations. The penetrance was
30% by the age of 50 and 67% by the age of 80. It
depended on the geographic origin: at 80 years of age,
it was 58 % in Europe, 76% in North America and 91%
in Australia [47]. These data suggest that UV increases
the penetrance of the CDKN2A mutations. 
There is no doubt that regardless of the
geographical origin, inclusion criteria or study methods,
CDKN2A constitutional alterations have been found
only in the minority of melanoma-prone families. In
families with multigenerational inheritance of MM there
remains a possibility that non-coding mutations of
CDKN2A or alterations in another tumour suppressor
gene predispose to familial melanoma. 
ARF
In 1995 two independent groups discovered that
CDKN2A shares exons 2 with another gene, ARF [48,
49]. The transcript, p14ARF is involved in the regulation
of the cell cycle and apoptosis [50]. It has also been
implicated in the pathogenesis of MM. The first exon
of ARF is unique, whereas its second exon is derived
from exon 2 of CDKN2A using a different reading
frame of the sequence. Up to now mutations in ARF
are reported to be present only in a few families
worldwide and are characterized by an aggregation of
MM and brain tumours [51]. Hewitt et al described
a germline mutation of ARF in patients affected with
melanoma or breast cancer from a family with multiple
melanomas and breast cancers [52], in an independent
study performed in our center no constitutional ARF
alterations in cases with familial aggregation of MM
and breast cancer were detected [40]. 
CDK4
In 1996 Zuo et al identified the CDK4 gene (12q13,
OMIM 123829) as a third MM susceptibility gene [48].
CDK4 is an oncogene that codes the cyclin-dependent
kinase 4 protein. Alterations in this gene are responsible
Fig. 2. Pedigree of a family with familial aggregations with MM and
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for the occurrence of very small proportions of familial
MM. Up to now germline CDK4 mutations have been
found in 3 families world-wide [36, 53, 54]. 
BRCA2
Mutations in BRCA2 (13q12, OMIM 600185),
acting in DNA repair, predispose to a range of cancer
types. The Breast Cancer Linkage Consortium estimates
the relative risk of melanoma to be 2.58 in BRCA2
carriers [55]. In 2002 Scott et al examined 71 patients
with ocular MM and pedigree and clinical data
suggestive of genetic background (bilateral cases,
positive family history for occurrence of MM, age at
diagnosis <50). He estimated the prevalence of
possible loss of function changes in BRCA2 in 3% of
patients with familial ocular melanoma [56]. No
germline BRCA2 mutations have been found in familial
skin MM to date. The penetrance of this gene is
unknown. Johannsson et al suggested that apart from
breast and ovarian cancer, the incidence of other
cancer types did not appear to be greatly increased in
BRCA2-associated families and did not warrant specific
clinical follow-up in mutation carriers [57]. 
NBS1
In 1998 Varon et al mapped and cloned the gene
responsible for Nijmegen breakage syndrome
characterized by spontaneous chromosomal instability,
immunodeficiency and predisposition to cancer. The
NBS1 gene is located on 8q21 (OMIM 602667) [58].
The NBS1 protein product, called nibrin (also referred
to as p95), is an integral component of
hMRE11/hRAD50/NBS1 nuclease complex, acting in
a double-strand break repair of human DNA [59]. 
Mutations in the NBS1 gene predispose to a range
of cancer types. We recently reported a greater than
expected prevalence of a founder 657del5 mutation
in the NBS1 gene in consecutive MM patients with
aggregations of breast cancer but this preliminary
finding needs to be confirmed [60]. No germline NBS1
mutations have been found in familial skin MM to date. 
CHK2
Malignant melanoma has been suggested to
belong to the clinical spectrum of Li-Fraumeni
syndrome (LFS, OMIM151623). In 1999 Blasina et al
and Chaturvedi et al independently identified
cell-cycle-checkpoint kinase 2 (CHK2, MIM 604373),
one of the key mediators of cellular responses to DNA
damage [61, 62]. The germline recurrent mutation in
the CHK2 gene (1100delC in exon 10) has been
found among two families with a phenotype suggestive
of Li-Fraumeni syndrome [63]. The tumour spectrum
of one of these families included MM. In a recent study
germline 1100delC mutation in the CHK2 gene was
reported in a patient with MM of the skin and three
metachronous malignancies belonging to LFS tumour
spectrum [64]. Thus, it seems that 1100delC of the
CHK2 gene may be responsible for occurrence of very
small proportions of MM cases, especially in families
with Li-Fraumeni syndrome or Li-Fraumeni-like
syndrome. No germline CHK2 mutations have been
found in familial skin MM to date. 
MLH1, MSH2
Germline mutations in the MLH1 (3p21, OMIM
120436) and MSH2 (2p22, OMIM 120435) genes
can lead to Muire-Torre syndrome, a variant of
hereditary non-polyposis colorectal cancer syndrome
with an increased frequency of occurrence of skin
malignancies, including MM. Both genes participate
in mismatch repair system of DNA. There is a report
of biallelic somatic inactivation of the MLH1 gene in
a primary skin melanoma [65]. It seems that a small
proportion of MLH1/MSH2 carriers could be at risk of
developing MM. No germline MLH1/MSH2 mutations
have been found in familial skin MM to date. 
XP-genes
MM, as well as a large number of basal cell
carcinoma and squamous cell cancer of the skin, is
a characteristic feature of xeroderma pigmentosum
syndrome (XP). XP is a group of disorders characterized
by high sensitivity to sunlight with the development of
skin malignancies at an early age. There are several
variants of XP caused by different XP susceptibility
genes, all of these genes are involved in UV-damaged
DNA repair. Three most common forms of XP variants
are: XPA (OMIM 278700), XPC (OMIM 278720) and
XPD (OMIM 278730). Recently an increased risk of
cutaneous melanoma in carriers of XPD polymorphisms
has been reported [66, 67]. 
In the literature we found no data about germline
mutations of XPA, XPC and XPD genes in familial
melanoma to date. 
Genes conferring a low risk of developing MM
MC1R
The MC1R gene (16q24, OMIM 155555) codes
a protein that acts as the receptor for
melanocyte-stimulating hormone (MSH). It has been
reported that some germline allelic variants of the MC1R
gene (Arg151Cys, Arg160Trp, Asp294His) conferred to
fair skin/red hair phenotype associated with an increased
risk of MM [68-70]. The same allelic variants
independently of skin type are associated with an
increased MM risk [69]. They also act as modifiers of the
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melanoma risk in carriers of the CDKN2A mutations by
increasing the penetrance from 50% to 84% in Australia
and from 18% to 55% in the Netherlands [71, 72]. 
Other factors
Inherited traits explaining part of the familial risk of
MM by modulating the response to UV radiation also
include: 
1) nevi, the risk of developing a melanoma
increases with the number of nevi and their clinically
atypical aspects (increase in size, red hue and/or
ABCDE criteria: (A) asymmetry, (B) vague border, (C)
variegated pigmentation, (D) diameter exceeding
5 mm, (E) elevation) [73, 74]. This risk is especially
high in dysplastic nevus syndrome [75]. Recent twin
studies indicate the contribution of both genetic factors
and sun exposure to the number of nevi [76]. Analysis
of familial transmission of nevi suggests a more
complex mechanism than a single-gene effect [77].
Atypical nevi, present either in the familial or sporadic
setting are regarded by dermatologists as strong
indicators of an increased melanoma risk and should
be either monitored or excised. 
It should be mentioned that MM, especially
a nodular type, can arise in apparently healthy skin; 
2) skin type (liability to tan), the risk of MM is
increased in persons with fair skin (limited capabilities
of tanning) and red hair [78]. 
Conclusions 
MM is a highly heterogeneous tumour type from
a genetic perspective. Pedigree and clinical data of
a proportion of familial MM suggest a hereditary
syndrome caused by germline alterations of a single
gene. Several different genes are involved in the
development of MM. However, even when taken together
they are responsible for less than 20% of all MM cases.
It is thus necessary to perform association studies focused
on identifying genetic markers that could be used in
identifying patients with a high risk of MM. Evaluation
of aggregations of MM and other malignancies, like
breast cancer, could be essential in identifying relatives
of MM probands being at high risk of developing
malignancies other than MM. The ultimate goal is to
apply in these cases prevention recommendations and
surveillance protocols to reduce the disease risk. 
Prevention recommendations
The use of higher sun protection factor sunscreens,
avoidance of physical trauma of nevi. 
Surveillance protocols
In the case of familial MM: melanoma patient, his
first- and second degree relatives: half-yearly careful
skin examination by the dermatologist. In cases with
atypical nevi: skin examination should be performed
every three months. Random removal of a large
number of atypical nevi is not recommended. The
removal of lesions in susceptible individuals should be
indicated by clinical signs of malignant transformation
(increase of size, red hue, bleeding, pruritus, etc.). 
Additionally the melanoma patient and his relatives
should be screened for pancreatic cancer with an
annual ultrasonography and computer tomography
every three years. 
In cases with familial aggregations with MM and
malignancies (at least two cases) at different sites of
origin, especially with MM diagnosed under the age
of 55: breast cancer surveillance is suggested (yearly
physical examination, ultrasonography and finally
mammography starting from the age of 25). 
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